Rapt Therapeutics Receives $48.44 Average Target Price from Analysts

Shares of the clinical-stage biotech company have received a 'Hold' rating from analysts.

Published on Mar. 10, 2026

Got story updates? Submit your updates here. ›

Shares of Rapt Therapeutics (NASDAQ:RAPT) have received an average recommendation of 'Hold' from the thirteen brokerages currently covering the firm, according to Marketbeat. The average 12-month target price among analysts is $48.44.

Why it matters

As a clinical-stage biotech company, Rapt Therapeutics' stock performance and analyst ratings are closely watched by investors interested in the company's progress with its pipeline of novel therapeutics for autoimmune and allergic diseases.

The details

One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, one has given a buy rating and one has given a strong buy rating to the company. Analysts at Barclays, JPMorgan Chase & Co., Wells Fargo & Company, and Piper Sandler have all recently adjusted their ratings and price targets for Rapt Therapeutics.

  • Rapt Therapeutics' stock opened at $58.02 on Thursday.
  • The company's 50-day simple moving average is $50.39 and its 200-day simple moving average is $35.01.

The players

Rapt Therapeutics

A clinical-stage biotechnology company developing novel therapeutics for autoimmune and allergic diseases.

Barclays

An investment bank that lowered its rating on Rapt Therapeutics from 'overweight' to 'equal weight' and set a $58.00 price target.

JPMorgan Chase & Co.

An investment bank that raised its price target on Rapt Therapeutics from $55.00 to $57.00 and maintained an 'overweight' rating.

Wells Fargo & Company

A financial services company that cut its rating on Rapt Therapeutics from 'overweight' to 'equal weight' and set a $58.00 target price.

Piper Sandler

An investment bank that downgraded Rapt Therapeutics from 'overweight' to 'neutral' and set a $58.00 target price.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

The takeaway

As a clinical-stage biotech company, Rapt Therapeutics' stock performance and analyst ratings are closely watched by investors interested in the company's progress with its pipeline of novel therapeutics for autoimmune and allergic diseases.